[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hassanien et al., 2020 - Google Patents

In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis

Hassanien et al., 2020

View HTML
Document ID
10778962478385236083
Author
Hassanien S
Bassman J
Perrien Naccarato C
Twarozynski J
Traynor J
Iula D
Anand J
Publication year
Publication venue
Drug testing and analysis

External Links

Snippet

Opioids are widely misused and account for almost half of overdose deaths in the United States. The cost in terms of lives, health care, and lost productivity is significant and has been declared a national crisis. Fentanyl is a highly potent mu opioid receptor (MOR) …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members

Similar Documents

Publication Publication Date Title
Hassanien et al. In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis
Norman et al. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market
Jannetto et al. The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European Union
Strayer et al. LC-MS/MS-based method for the multiplex detection of 24 fentanyl analogues and metabolites in whole blood at sub ng mL–1 concentrations
Marchei et al. New synthetic opioids in biological and non-biological matrices: A review of current analytical methods
Krotulski et al. The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent‐4en and but‐3en analogues including MDMB‐4en‐PINACA
Catlin et al. Tetrahydrogestrinone: discovery, synthesis, and detection in urine
Truver et al. 5F‐MDMB‐PICA metabolite identification and cannabinoid receptor activity
Grigoryev et al. The detection of the urinary metabolites of 3‐[(adamantan‐1‐yl) carbonyl]‐1‐pentylindole (AB‐001), a novel cannabimimetic, by gas chromatography‐mass spectrometry
Verougstraete et al. First report on brorphine: the next opioid on the deadly new psychoactive substance horizon?
Liu et al. Identification and analytical characterization of nine synthetic cathinone derivatives N‐ethylhexedrone, 4‐Cl‐pentedrone, 4‐Cl‐α‐EAPP, propylone, N‐ethylnorpentylone, 6‐MeO‐bk‐MDMA, α‐PiHP, 4‐Cl‐α‐PHP, and 4‐F‐α‐PHP
Allibe et al. Fatality involving ocfentanil documented by identification of metabolites
Nan et al. Investigation of fragmentation pathways of fentanyl analogues and novel synthetic opioids by electron ionization high-resolution mass spectrometry and electrospray ionization high-resolution tandem mass spectrometry
Angerer et al. Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL‐PEGACLONE
Blanckaert et al. Analytical characterization of “etonitazepyne,” a new pyrrolidinyl‐containing 2‐benzylbenzimidazole opioid sold online
Antonides et al. Shape matters: the application of activity‐based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug‐infused papers seized in prisons
Blakey et al. What's in fake ‘Xanax’?: a dosage survey of designer benzodiazepines in counterfeit pharmaceutical tablets
Gilbert et al. Hitting the Jackpot–development of gas chromatography–mass spectrometry (GC–MS) and other rapid screening methods for the analysis of 18 fentanyl‐derived synthetic opioids
Bertol et al. Advances in new psychoactive substances identification: the URI To. N. Consortium
McLaughlin et al. Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N‐methoxy positional isomer, N‐methoxymephedrone
Wohlfarth et al. Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS
Shevyrin et al. Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1, 2, 4-oxadiazole. The first detection in illicit market of new psychoactive substances
Senthilkumar et al. One‐Pot Synthesis of Hydrophobically Modified Iminosugar C‐Alkynylglycosides: Facile Synthesis of Polyhydroxy Tetrahydroindolizines
Presley et al. Assessment of synthetic cannabinoid FUB‐AMB and its ester hydrolysis metabolite in human liver microsomes and human blood samples using UHPLC–MS/MS
Gilbert et al. Synthesis, characterisation, detection and quantification of a novel hexyl-substituted synthetic cannabinoid receptor agonist:(S)-N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-hexyl-1H-indazole-3-carboxamide (ADB-HINACA)